NEW YORK, NY / ACCESS Newswire / January 31, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...

For the 18th year running, Apple has been named Fortune’s Most Admired Company. The rankings are based of a survey of more than 3,000 company execs across 30 countries. While Apple’s number one ...

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

Swedish screenwriter Pelle Rådström has won the first Nordic Series Script Award for his show Pressure Point . The award, ...

G/O Media is once again attempting to use AI to churn out content — while simultaneously warning that anything the AI ...

Novo Nordisk and Eli Lilly's motion to dismiss took aim at most of the counts asserted in the plaintiffs’ master long-form ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...